Guard Therapeutics Intl Investor Relations Material
Latest events
R&D Update
Guard Therapeutics Intl
Q1 2025
5 May, 2025
Q4 2024
20 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Guard Therapeutics Intl
Access all reports
Guard Therapeutics International AB is a Swedish biopharmaceutical company focused on the development of therapies for the diagnosis and treatment of acute kidney injuries. The company is most known for its investigational drug, ROSGard, a biological candidate designed to prevent kidney damage by mimicking the body's defense system against oxidative stress, thereby protecting, cleaning, and repairing exposed cells and tissues. Guard Therapeutics is headquartered in Stockholm, Sweden, and its shares are listed on the Nasdaq First North.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
GUARD
Country
🇸🇪 Sweden